Reaction

Gallbladder Operation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,956 reports · 74 co-occurring drugs

As of the last recalculation, Gallbladder Operation appears in 3,956 FAERS reports alongside 74 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 11.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Risankizumab-Rzaa	167	11.2	11.2
Pancrelipase	73	10.1	10.1
Upadacitinib	113	7.5	7.5
Ibrutinib	83	5.5	5.5
Valsartan And Hydrochlorothiazide	14	5.4	5.4
Hyoscyamine Sulfate	9	5.2	5.2
Bosentan	48	5.1	5.1
Calcium, Magnesium, Potassium, And Sodium Oxybates	8	4.9	4.9
Armodafinil	18	4.5	4.5
Epoprostenol	11	4.4	4.4
Glecaprevir And Pibrentasvir	9	4.3	4.3
Sodium Oxybate	53	4.3	4.3
Fluticasone Propionate And Salmeterol	32	4.1	4.1
Interferon Beta-1A	138	3.9	3.9
Patiromer	10	3.8	3.8
Nintedanib	22	3.7	3.7
Insulin Human	27	3.6	3.6
Drospirenone And Ethinyl Estradiol	30	3.6	3.6
Ranolazine	7	3.5	3.5
Infliximab-Dyyb	19	3.4	3.4
Cladribine	6	3.3	3.3
Riociguat	19	3.1	3.1
Teriparatide	65	3.1	3.1
Belimumab	18	3.0	3.0
Liraglutide	28	3.0	3.0
Ziprasidone Mesylate	8	3.0	3.0
Sitagliptin And Metformin Hydrochloride	12	2.9	2.9
Rotigotine	8	2.9	2.9
Golimumab	47	2.9	2.9
Etonogestrel And Ethinyl Estradiol	12	2.9	2.9
Certolizumab Pegol	62	2.8	2.8
Bimekizumab	11	2.7	2.7
Tafamidis	6	2.7	2.7
Oral Semaglutide	36	2.6	2.6
Linaclotide	13	2.6	2.6
Adalimumab	326	2.6	2.6
Macitentan	33	2.5	2.5
Icosapent Ethyl	4	2.5	2.5
Diclofenac Potassium	5	2.4	2.4
Etanercept	265	2.4	2.4
Ixekizumab	17	2.4	2.4
Voxelotor	10	2.3	2.3
Eptinezumab-Jjmr	4	2.3	2.3
Ambrisentan	54	2.3	2.3
Teriflunomide	19	2.2	2.2
Interferon Beta-1B	8	2.2	2.2
Natalizumab	75	2.2	2.2
Deferasirox	11	2.2	2.2
Niraparib	9	2.1	2.1
Esketamine Hydrochloride	7	2.1	2.1
Orlistat	10	2.0	2.0
Loratadine And Pseudoephedrine Sulfate	3	2.0	2.0
Methadone Hydrochloride	4	1.9	1.9
Naltrexone	11	1.9	1.9
Glatiramer Acetate	21	1.9	1.9
Dimethyl Fumarate	43	1.8	1.8
Voclosporin	3	1.8	1.8
Oxymorphone Hydrochloride	4	1.8	1.8
Exenatide	18	1.8	1.8
Palbociclib	31	1.7	1.7
Venetoclax	20	1.7	1.7
Abiraterone	4	1.5	1.5
Trifluridine And Tipiracil	3	1.5	1.5
Pirfenidone	11	1.4	1.4
Onabotulinumtoxina	20	1.4	1.4
Dornase Alfa	5	1.3	1.3
Elexacaftor, Tezacaftor, And Ivacaftor	3	1.3	1.3
Droxidopa	5	1.2	1.2
Guselkumab	8	1.2	1.2
Dupilumab	99	1.1	1.1
Evolocumab	30	1.0	1.0
Pimavanserin Tartrate	8	0.8	0.8
Apremilast	21	0.8	0.8
Copper	3	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.